System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alessio G Morganti is an expert in Radiotherapy at Policlinico S.Orsola-Malpighi (Italy). As of October 2026, ScienceLeadR ranks Alessio G Morganti in the top 1% of experts worldwide for Urogenital Neoplasms and Palliative Care. Alessio G Morganti has authored 895 publications, the most recent in 2026, and is an investigator in 36 clinical trials, 6 of them ongoing. SLR score: 3,244 (community average: 125). How the SLR is computed.

LeadR Profile

Alessio G Morganti Policlinico S.Orsola-Malpighi Italy
3 244 ScienceLeadR Reputation 3244

Unlock

Register Login
Network Map

Radiotherapy

Subspecialties: Oncology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026
Source: PubMed

Policlinico S.Orsola-Malpighi

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 895

Citations

Citations: 9 565 1st author: 42 Last author: 298 Unique author: 0

Main journals

Radiother Oncol 318
Int J Radiat Oncol Biol Phys 43
Rays 36
Cancers (Basel) 35
Phys Med 29

Best Journals

Lancet Oncol 2
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Interventional radiation immune-boosting (iRIB). The role of concomitant interventional radiotherapy (modern brachytherapy) in immunotherapy: A hypothesis-generating systematic review.
PMID 42877491 — radiotherapy, brachytherapy, neoplasms, immunotherapy, adrenocortical carcinoma, therapeutics, wounds and injuries, dose fractionation, radiation		J Contemp Brachytherapy20260
Hypoxia-Targeting Strategies in Radiotherapy and Nitroimidazole-Based Radiosensitizers: A Narrative Review and Translational Perspectives.
PMID 42793219 — radiotherapy, cells, uterine cervical neoplasms, neoplasms, hypoxia, nitroimidazoles, tumor hypoxia, colorectal neoplasms		Curr Issues Mol Biol20261
Impact of genetic polymorphisms on the response to transdermal fentanyl in cancer patients-a single-center, prospective, biological study.
PMID 42676478 — research design, pharmacogenetics, pain, neoplasms, analgesics, polymorphism, genetic, fentanyl, pharmacokinetics, cancer pain		Front Pain Res (Lausanne)20260
Image-guided adaptive interventional radiotherapy (modern brachytherapy) boost for vaginal recurrences.
PMID 42322514 — radiotherapy, mortality, brachytherapy, neoplasms, drug therapy, radiology, neoplasm metastasis, therapeutics, chemotherapy		Radiol Med20260
Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.
PMID 42636843 — radiotherapy, ovary, neoplasms, classification, ovarian neoplasms, research, therapeutics, peritoneal diseases		Lancet Oncol Top journal20260

Clinical Studies 36

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 15 Study Director: 7

By phase:

N/A 28
Phase 2 4
Phase 3 3
Phase 4 1

By status:

Completed 15
Unknown 12
Recruiting 6
Active not recruiting 3

By type:

Interventional 28
Observational 8

By Monocentric/Multicentric:

monocentric 31
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer a rANdomized trial PERSIAN
2022-501894-37-00 — radiotherapy, androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics		Phase 2Recruiting2023
Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations
NCT06903312 — radiotherapy, cells, neoplasms, multiple chronic conditions, nephrectomy, axitinib, kidney, mastectomy, segmental, carcinoma, renal cell, immunotherapy, kidney neoplasms, nivolumab, therapeutics, ipilimumab, random allocation, carcinoma		Phase 4Recruiting2025
Evaluation of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Uterine Neoplasms
NCT06774482 — radiotherapy, neoplasms, therapeutics, uterine neoplasms		N/ARecruiting2021
Assessment of Different Therapeutic Strategies in Patients With Head and Neck Neoplasms Treated With Radiotherapy
NCT06773039 — radiotherapy, data collection, neoplasms, head and neck neoplasms, therapeutics		N/ARecruiting2021
Evaluation of Toxicities in Patients Treated With Palliative Radiotherapy at Policlinico Sant Orsola of Bologna
NCT06760806 — radiotherapy, therapeutics, palliative care		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS